FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Solo a fini di ricerca. Disposizione completa →

Libreria Peptidica

Lemon Bottle

Lemon Bottle Fat Dissolve

Weight Loss & Metabolic

Lemon Bottle is a branded lipolytic injection solution that is not a peptide but rather a combination of riboflavin (vitamin B2), bromelain (pineapple-derived enzyme), and lecithin, marketed primarily in the aesthetic medicine market for non-surgical fat dissolution. Originating from South Korea, it has gained rapid popularity in cosmetic clinics worldwide as an alternative to traditional deoxycholic acid-based fat dissolving injections. The product claims to induce adipocyte lipolysis and fat cell destruction through its combined enzymatic and emulsifying components.

Meccanismo d'azione

Injectable fat-dissolving solution containing riboflavin, lecithin, and bromelain. Disrupts adipocyte cell membranes.

Protocolli di ricerca

Solo per scopi di ricerca. Non è consiglio medico.

Administered by trained practitioners. 2-5ml per treatment area, injected subcutaneously. Treatments spaced 2-4 weeks apart.

Note di ricerca

Clinical Research Status

Lemon Bottle has not undergone rigorous peer-reviewed clinical trials or regulatory approval by the FDA, EMA, or other major pharmaceutical regulatory bodies for fat dissolution. The product is marketed as a "lipolytic solution" rather than a pharmaceutical, allowing it to be sold in many jurisdictions without the clinical trial data required for drug approval. Anecdotal clinical results from aesthetic practitioners are widely shared on social media and at industry conferences, but independent verification of efficacy claims remains lacking.

Key Published Findings

No peer-reviewed publications in indexed medical journals have specifically evaluated Lemon Bottle's efficacy or mechanism of action as a combined formulation. Individual components have established biochemistry: bromelain has proteolytic and anti-inflammatory properties, lecithin (phosphatidylcholine) has been studied for injection lipolysis, and riboflavin participates in fatty acid oxidation. However, the specific concentrations, combination ratios, and delivery method used in Lemon Bottle have not been independently validated for fat reduction.

Safety Profile

Reports of adverse effects include significant swelling, bruising, pain at injection sites, skin necrosis in rare cases, and irregular contour deformities when administered improperly. Without standardized clinical trials, the true incidence of complications is unknown and likely underreported in the commercial aesthetic setting. Concerns have been raised by medical professionals regarding the lack of long-term safety data, unknown product consistency between batches, and potential risks of injecting enzymatic compounds into subcutaneous tissue.

Comparison to Related Compounds

Unlike Kybella (deoxycholic acid), which is FDA-approved specifically for submental fat and has completed rigorous Phase III clinical trials, Lemon Bottle has no regulatory approval for any fat reduction indication. Compared to traditional phosphatidylcholine/deoxycholate (PCDC) injection lipolysis, Lemon Bottle claims to produce less swelling and downtime, though this has not been verified in comparative studies. The bromelain component distinguishes it from other lipolytic injectables, theoretically providing enzymatic fat breakdown, but optimal concentrations for subcutaneous injection have not been established.

Community Observations

The aesthetic community is divided on Lemon Bottle, with some practitioners reporting impressive results in small treatment areas while others express concern about the lack of regulatory oversight and clinical evidence. Social media has amplified its popularity, particularly on TikTok and Instagram, leading to widespread use despite medical community reservations. Price points are significantly lower than FDA-approved alternatives, contributing to its market adoption but also raising questions about product quality and manufacturing standards.

Semplifichro

N/A (not a peptide)

Riconcimimento

Pre-mixed solution (no reconstitution)

Conservazione

Lyofilizzato

Refrigerate 2-8C.

Riconcimato

Use immediately after opening.

Stato legale USA

Unregulated cosmetic product

Anche noto come

Lemon Bottle Fat Dissolve

Domande frequenti

Che cos'è Lemon Bottle?

Lemon Bottle is a branded lipolytic injection solution that is not a peptide but rather a combination of riboflavin (vitamin B2), bromelain (pineapple-derived enzyme), and lecithin, marketed primarily in the aesthetic medicine market for non-surgical fat dissolution. Originating from South Korea, it has gained rapid popularity in cosmetic clinics worldwide as an alternative to traditional deoxycholic acid-based fat dissolving injections. The product claims to induce adipocyte lipolysis and fat cell destruction through its combined enzymatic and emulsifying components.

Come agisce Lemon Bottle?

Injectable fat-dissolving solution containing riboflavin, lecithin, and bromelain. Disrupts adipocyte cell membranes.

Qual è lo stato normativo di Lemon Bottle negli Stati Uniti?

Unregulated cosmetic product

Qual è l'emivita di Lemon Bottle?

N/A (not a peptide)

Con quali altri nomi è noto Lemon Bottle?

Lemon Bottle Fat Dissolve

Peptide Contacts fornisce riassunti basati su ricerche a fini informativi soltanto. Non ospitiamo, distribuiamo o endossiamo le comunicazioni dei fornitori. Tutti i certificati di analisi, certificati GMP e comunicazioni del fornitore devono essere richiesti e verificati direttamente dall'acquirente. Niente su questa piattaforma costituisce consigli legali, medici o professionali. I utenti sono responsabili unicamente della verifica delle credenziali dei fornitori e dell'assicurazione del rispetto di tutte le leggi locali, regionali e federali applicabili prima di acquistare qualsiasi chimica di ricerca. L'uso di questa piattaforma costituisce l'accettazione piena della responsabilità personale.

Leggi l'intera dichiarazione di responsabilità